On Friday, 27th May 2022, the Centers for Disease Control and Prevention (CDC) of the United States has published the new recommendations or guidelines by US CDC’s group of the independent experts on a smallpox vaccine that has been limiting the use only for the people who has been working closely with the viruses as monkeypox.
The Jynneos vaccine, which has been developed by Bavarian Nordic, is going to be available for certain healthcare workers and the laboratory personnel at time, when monkeypox disease infections has now spread across the United States, Europe and beyond. The vaccine for Monkeypox had been approved in the United States in 2019 for the purpose of preventing smallpox and monkeypox in the high risk people above 18 years of age.
The officials of the US CDC said, they had been in the process of releasing some of the doses of the Jynneos vaccine for the people in contact with the known patients of the monkeypox virus. The officials also said that, there had been more than 100 million doses of the old small pox vaccine called as ACAM2000, which has been made by Emergent BioSolutions, which is having the significant side effects.
Till now, there had been around 300 confirmed cases of monkeypox in around 20 countries, where the corona virus had not been circulating previously and the World Health Organization (WHO) has called for quick action from the countries for stopping the spread of the monkeypox virus or disease.